No registrations found.
Source
Brief title
Health condition
Prostate cancer
CRPC
HSPC
Metastatic prostate cancer
Sponsors and support
Intervention
No registrations found.
Outcome measures
Primary outcome
The rate of successfully cultured organoids from CTCs obtained by LA.
Secondary outcome
The collection efficiency of CTCs by LA.
Background summary
Within the CIRCLE study, large numbers of circulating tumor cells (CTC) are derived from patients with metastatic prostate cancer by leukapheresis to enable culturing of organoids as a new prostate cancer model for drug screening.
Study objective
We hypothesize that it is possible to culture circulating tumor cells obtained by leukapheresis into organoids.
Study design
Enrolment should be completed within 2 years.
Intervention
leukapheresis
A.C. de Jong
Postbus 2040
Rotterdam 3000 CA
The Netherlands
Tel.: 010-7044375
a.c.dejong@erasmusmc.nl
A.C. de Jong
Postbus 2040
Rotterdam 3000 CA
The Netherlands
Tel.: 010-7044375
a.c.dejong@erasmusmc.nl
Inclusion criteria
- Metastatic prostate cancer.
- Intention to start (new) line of systemic treatment.
- Written informed consent of the patient.
- Age ≥ 18 years.
- WHO performance status ≤2.
- ≥ 2 adequate peripheral veins as access point for leukapheresis.
Exclusion criteria
- Low CTC count.
- Patients with a known hypersensitivity to the used LA-anticoagulant (ACD).
- Current ADT
- Hemorrhage disease and/or coagulation disorder.
- Inadequate liver function.
- Inadequate renal function.
- Inadequate hematology and coagulation status.
- Use of anticoagulation at time of leukapheresis, unless medication can either be safely stopped or counteracted.
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
NTR-new | NL6019 |
NTR-old | NTR6150 |
Other | METC // ABR-nummer : MEC-2016-449 // NL57710.078.16. |